Figure 4

Effects of FLX22 on locomotor activity and anxiety-related behavior. (A) FLX22 reduced time spent in the center of the open field (z = 4.766, p < 0.0001), but had no significant effect on the total distance traveled (z = 0.08, p = 0.9361, CNT: n = 25, FLX22: n = 28). (B) FLX22 reduced time spent in the light compartment in the light/dark transition test (z = 3.185, p = 0.0015) and increased the latency to enter the light compartment (z = 2.217, p = 0.0267), but had no significant effects on the total distance traveled (z = 0.176, p = 0.8602) or the number of transition between two compartments (z = 0.983, p = 0.3253, CNT: n = 17, FLX22: n = 21). Two fluoxetine-treated mice did not enter the light compartment. (C) FLX22 increased the total distance traveled (z = 2.69, p = 0.0072) and the number of entries into arms (z = 2.465, p = 0.0137), and decreased relative entry into open arms (z = 2.704, p = 0.0069), but had no significant effect on time in open arms (z = 1.225, p = 0.2205) in the elevated plus-maze test (CNT: n = 18, FLX22: n = 21). Percent values are calculated as in Figure 3.